Seres Therapeutics

Submitted by Anonymous (not verified) on
We have an exclusive agreement with Seres to jointly commercialize SER-109, Seres' investigational oral microbiome therapeutic for recurrent Clostridium difficilie infection. If approved, it would be the first-ever FDA-approved microbiome therapeutic. The agreement to co-commercialize SER-109 in the US and Canada represents the expansion of an existing strategic collaboration between the companies. We already have commercial rights to Seres’ investigational treatments for CDI and inflammatory bowel disease outside of the US and Canada, and with this expansion, Nestlé Health Science becomes Seres’ global collaborator in SER-109.
Choose partners
Image
Seres Therapeutics Logo